Novartis’ Kisqali shows 25% reduction in breast cancer recurrence
HQ Team June 3, 2023: Novartis breast cancer drug Kisqali cut the risk of recurrence of the disease by more than 25% in
"This new work expands on important issues, such as the clinical evidence on endometriosis in adolescents and postmenopausal women."
HQ Team June 2, 2023: Instead of breaking internal walls in a building to connect two room spaces, scientists have developed a technique